Date:
April 5, 2021
Issue #:
1621
Summary:
The FDA has issued an Emergency Use Authorization
(EUA) for Lilly’s investigational monoclonal antibodies
bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016)
to be administered together for treatment of
mild to moderate COVID-19 in patients ≥12 years old
who weigh ≥40 kg and are at high risk of progressing
to severe disease and/or hospitalization (see Table 1).
Bamlanivimab received an EUA for use as monotherapy
in such patients in November 2020. Regeneron’s
investigational monoclonal antibodies casirivimab
(REGN10933) and imdevimab (REGN10987) are also
authorized for use together for the same indication.
(EUA) for Lilly’s investigational monoclonal antibodies
bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016)
to be administered together for treatment of
mild to moderate COVID-19 in patients ≥12 years old
who weigh ≥40 kg and are at high risk of progressing
to severe disease and/or hospitalization (see Table 1).
Bamlanivimab received an EUA for use as monotherapy
in such patients in November 2020. Regeneron’s
investigational monoclonal antibodies casirivimab
(REGN10933) and imdevimab (REGN10987) are also
authorized for use together for the same indication.